# NExT DTP-23-019 GMP PRODUCTION OF 40MG CAPSULES OF Z-ENDOXIFEN

> **NIH NIH N02** · IRISYS, INC. · 2023 · $140,000

## Abstract

The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) develops cancer therapeutic agents under the Developmental Therapeutics Program (DTP). Part of the DTP services includes formulation and production of clinical dosage forms of the agents selected by DCTD for further development.

## Key facts

- **NIH application ID:** 10948454
- **Project number:** 75N98019D00058-0-759102300002-1
- **Recipient organization:** IRISYS, INC.
- **Principal Investigator:** ROBERT GIANNINI
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $140,000
- **Award type:** —
- **Project period:** 2023-04-24 → 2023-07-23

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10948454

## Citation

> US National Institutes of Health, RePORTER application 10948454, NExT DTP-23-019 GMP PRODUCTION OF 40MG CAPSULES OF Z-ENDOXIFEN (75N98019D00058-0-759102300002-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10948454. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*